Chronic kidney disease and albuminuria in arterial hypertension

Current Hypertension Reports

Volumn 12, Issue 5, 2010, Pages 335-341

  Leoncini, Giovanna ^a   Viazzi, Francesca ^a   Pontremoli, Roberto ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

ACE inhibitors; ACE I; Angiotensin II receptor blockers; Angiotensin converting enzyme inhibitors; Antihypertensive treatment; ARB; Chronic kidney disease; Hypertension; Progression; Proteinuria; RAAS; Renal protection; Renin angiotensin aldosterone system

Indexed keywords

ALDOSTERONE ANTAGONIST; ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; LISINOPRIL; LOSARTAN; PLACEBO; RAMIPRIL; SPIRONOLACTONE; TELMISARTAN; TRANDOLAPRIL; VALSARTAN; VERAPAMIL;

ALBUMINURIA; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY INJURY; MICROALBUMINURIA; MONOTHERAPY; PHARMACOLOGICAL BLOCKING; POTASSIUM BLOOD LEVEL; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ALBUMINURIA; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE MONITORING, AMBULATORY; CALCIUM CHANNEL BLOCKERS; CLINICAL TRIALS AS TOPIC; EARLY DIAGNOSIS; HEART DISEASES; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; RENIN; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME;

EID: 77958456490     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-010-0141-3     Document Type: Review

References (47)

1. QL Zhang D Rothenbacher 2008 Prevalence of chronic kidney disease in population-based studies: systematic review BMC Public Health 8 117 10.1186/1471-2458-8-117 18405348 (Pubitemid 351678123)
2. J Coresh E Selvin LA Stevens, et al. 2007 Prevalence of chronic kidney disease in the United States JAMA 298 2038 2047 1:CAS:528:DC%2BD2sXht1yjsLnM 10.1001/jama.298.17.2038 17986697 (Pubitemid 350074801)
3. DS Keith GA Nichols CM Gullion, et al. 2004 Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization Arch Intern Med 164 659 663 10.1001/archinte.164.6.659 15037495 (Pubitemid 38392981)
4. AS Go GM Chertow D Fan, et al. 2004 Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 351 1296 1305 1:CAS:528:DC%2BD2cXnvFSgtr8%3D 10.1056/NEJMoa041031 15385656 (Pubitemid 39268908)
5. BC Astor SI Hallan ER Miller 3rd, et al. 2008 Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population Am J Epidemiol 167 1226 1234 10.1093/aje/kwn033 18385206 (Pubitemid 351670638)
6. United States Renal Data System, USRDS 2008 Annual Data Report: Atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2008.
7. CY Hsu CE McCulloch J Darbinian, et al. 2005 Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease Arch Intern Med 165 923 928 10.1001/archinte.165.8.923 15851645 (Pubitemid 40563240)
8. National Kidney Foundation 2002 K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification Am J Kidney Dis 39 2 Suppl 1 S1 S266
9. G Mancia G De Backer A Dominiczak, et al. 2007 ESH-ESC Task Force on the Management of Arterial Hypertension: 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension J Hypertens 25 1751 1762 1:CAS:528:DC%2BD2sXpslalsb0%3D 10.1097/HJH.0b013e3282f0580f 17762635 (Pubitemid 47356612)
10. LC Plantinga ER Miller 3rd LA Stevens, et al. 2009 Centers for Disease Control and Prevention Chronic Kidney Disease Surveillance Team: Blood pressure control among persons without and with chronic kidney disease: US trends and risk factors 1999-2006 Hypertension 54 47 56 1:CAS:528:DC%2BD1MXntVyrtro%3D 10.1161/HYPERTENSIONAHA.109.129841 19470881
11. JC Peterson S Adler JM Burkart, et al. 1995 Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study Ann Intern Med 123 754 762 1:STN:280:DyaK28%2FjtVOntw%3D%3D 7574193
12. AH Brantsma SJ Bakker HL Hillege, et al. 2008 PREVEND Study Group: Cardiovascular and renal outcome in subjects with K/DOQI stage 1-3 chronic kidney disease: the importance of urinary albumin excretion Nephrol Dial Transplant 23 3851 3858 1:CAS:528:DC%2BD1cXhsVWlsrrP 10.1093/ndt/gfn356 18641082
13. K Iseki K Kinjo C Iseki S Takishita 2004 Relationship between predicted creatinine clearance and proteinuria and the risk of developing ESRD in Okinawa, Japan Am J Kidney Dis 44 806 814 1:CAS:528:DC%2BD2cXhtVahtLrE 15492946
14. D de Zeeuw G Remuzzi HH Parving, et al. 2004 Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL Kidney Int 65 2309 2320 10.1111/j.1523-1755.2004.00653.x 15149345 (Pubitemid 38670018)
15. D de Zeeuw G Remuzzi HH Parving, et al. 2004 Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy Circulation 110 921 927 10.1161/01.CIR.0000139860.33974.28 15302780 (Pubitemid 39128617)
16. WB Eijkelkamp Z Zhang G Remuzzi, et al. 2007 Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial J Am Soc Nephrol 18 1540 1546 1:CAS:528:DC%2BD2sXls1Glu7Y%3D 10.1681/ASN.2006050445 17409317 (Pubitemid 46717521)
17. RC Atkins EM Briganti JB Lewis, et al. 2005 Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy Am J Kidney Dis 45 281 287 10.1053/j.ajkd.2004.10.019 15685505 (Pubitemid 40431053)
18. P Gaede L Tarnow P Vedel, et al. 2004 Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria Nephrol Dial Transplant 19 2784 2788 10.1093/ndt/gfh470 15328385 (Pubitemid 39480973)
19. HM Siragy RM Carey 2010 Role of the intrarenal renin-angiotensin- aldosterone system in chronic kidney disease Am J Nephrol 31 541 550 1:CAS:528:DC%2BC3cXnvFWhsr4%3D 10.1159/000313363 20484892
20. EJ Lewis LG Hunsicker WR Clarke T Berl, et al. 2001 Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 851 860 1:CAS:528:DC%2BD3MXntlelsLg%3D 10.1056/NEJMoa011303 11565517
21. BM Brenner ME Cooper D de Zeeuw, et al. 2001 RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 861 869 1:CAS:528: DC%2BD3MXntlelsLk%3D 10.1056/NEJMoa011161 11565518
22. XR Huang WY Chen LD Truong HY Lan 2003 Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease J Am Soc Nephrol 14 1738 1747 1:CAS:528:DC%2BD3sXksV2ju78%3D 10.1097/01.ASN.0000071512.93927.4E 12819233 (Pubitemid 36750469)
23. F Fyhrquist O Saijonmaa 2008 Renin-angiotensin system revisited. J Intern Med 264 224 236 1:STN:280:DC%2BD1cngsFOmtQ%3D%3D
24. J Staessen P Lijnen R Fagard, et al. 1981 Rise in plasma concentration of aldosterone during longterm angiotensin II suppression J Endocrinol 91 457 465 1:CAS:528:DyaL38XhtFGlurw%3D 10.1677/joe.0.0910457 7035596
25. R Kunz C Friedrich M Wolbers JF Mann 2008 Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease Ann Intern Med 148 30 48 17984482 This meta-analysis shows no difference between ACE inhibitors and ARBs in reducing urinary protein excretion. Proteinuria reduction is greater with dual RAAS blockade than with single-drug therapy.
26. N Nakao A Yoshimura H Morita, et al. 2003 Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial Lancet 361 117 124 1:CAS:528:DC%2BD3sXisl2rtQ%3D%3D 10.1016/S0140-6736(03)12229-5 12531578 (Pubitemid 36092015)
27. The Editors of The Lancet: Retraction-Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. The Lancet 2009, 374:1226.
28. JF Mann RE Schmieder M McQueen, et al. 2008 ONTARGET investigators: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial Lancet 372 547 553 1:CAS:528:DC%2BD1cXpvFKgsLs%3D 10.1016/S0140-6736(08)61236-2 18707986 Renal data from the ONTARGET study demonstrated no renal benefit from dual RAAS inhibitors.
29. LF Fried W Duckworth JH Zhang, et al. 2009 VA NEPHRON-D Investigators: Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D) Clin J Am Soc Nephrol 4 361 368 1:CAS:528:DC%2BD1MXjslagur8%3D 10.2215/CJN.03350708 19118120
30. CT Wang LX Zou LG Navar 1997 Renal responses to AT1 blockade in angiotensin II-induced hypertensive rats J Am Soc Nephrol 8 535 542 1:CAS:528:DyaK2sXivVGnsbk%3D 10495782
31. H Rakugi DS Wang VJ Dzau RE Pratt 1994 Potential importance of tissue angiotensin-converting enzyme inhibition in preventing neointima formation Circulation 90 449 455 1:CAS:528:DyaK2cXmsVGlsb4%3D 7517799
32. J Wagner F Gehlen A Ciechanowicz E Ritz 1999 Angiotensin II receptor type 1 gene expression in human glomerulonephritis and diabetes mellitus J Am Soc Nephrol 10 545 551 1:STN:280:DyaK1M7ntFKisQ%3D%3D 10073605
33. RE Schmieder AU Klingbeil EH Fleischmann, et al. 2005 Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study J Am Soc Nephrol 16 3038 3045 1:CAS:528: DC%2BD2MXhtFegtLnF 10.1681/ASN.2005020138 16120821 (Pubitemid 44743501)
34. K Rossing KJ Schjoedt BR Jensen, et al. 2005 Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria Kidney Int 68 1190 1198 1:CAS:528:DC%2BD2MXhtVCjt73E 10.1111/j.1523-1755.2005.00511.x 16105050 (Pubitemid 43246436)
35. NK Hollenberg HH Parving G Viberti, et al. 2007 Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus J Hypertens 25 1921 1926 1:CAS:528:DC%2BD2sXpslalu74%3D 10.1097/HJH.0b013e328277596e 17762658 (Pubitemid 47356634)
36. E Burgess N Muirhead P Rene de Cotret, et al. 2009 SMART (Supra Maximal Atacand Renal Trial) Investigators: Supramaximal dose of candesartan in proteinuric renal disease J Am Soc Nephrol 20 893 900 1:CAS:528: DC%2BD1MXltFyjsro%3D 10.1681/ASN.2008040416 19211712 Supramaximal doses of candesartan provide a greater reduction in proteinuria than conventional doses (ie, 16 mg/d) regardless of blood pressure reduction.
37. FF Hou D Xie X Zhang, et al. 2007 Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency J Am Soc Nephrol 18 1889 1898 1:CAS:528:DC%2BD2sXnt1WjsL0%3D 10.1681/ASN.2006121372 17494885 (Pubitemid 46870325)
38. JA Staessen Y Li T Richart 2006 Oral renin inhibitors Lancet 368 1449 1456 1:CAS:528:DC%2BD28XhtFSntb3M 10.1016/S0140-6736(06)69442-7 17055947 (Pubitemid 44573444)
39. HH Parving F Persson JB Lewis, et al. 2008 AVOID Study Investigators: Aliskiren combined with losartan in type 2 diabetes and nephropathy N Engl J Med 358 2433 2446 1:CAS:528:DC%2BD1cXmvFKmtLY%3D 10.1056/NEJMoa0708379 18525041 This study was the first demonstration of greater proteinuria reduction with the novel direct renin blocker, aliskiren, in addition to an ARB in patients with hypertension and diabetic nephropathy. (Pubitemid 351793017)
40. HH Parving BM Brenner JJ McMurray, et al. 2009 Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design Nephrol Dial Transplant 24 1663 1671 1:CAS:528:DC%2BD1MXkvFKjsLs%3D 10.1093/ndt/gfn721 19145003
41. SD Navaneethan SU Nigwekar AR Sehgal GF Strippoli 2009 Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis Clin J Am Soc Nephrol 4 542 551 1:CAS:528:DC%2BD1MXktFKis78%3D 10.2215/CJN.04750908 19261819
42. P Ruggenenti A Fassi AP Ilieva, et al. 2004 Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators: preventing microalbuminuria in type 2 diabetes N Engl J Med 351 1941 1951 1:CAS:528:DC%2BD2cXps1Wlt70%3D 10.1056/NEJMoa042167 15516697 (Pubitemid 39447135)
43. BE de Galan V Perkovic T Ninomiya, et al. 2009 ADVANCE Collaborative Group: Lowering blood pressure reduces renal events in type 2 diabetes J Am Soc Nephrol 20 883 892 10.1681/ASN.2008070667 19225038
44. R Bilous N Chaturvedi AK Sjølie, et al. 2009 Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials Ann Intern Med 151 11 20 19451554
45. H Haller GC Viberti A Mimran, et al. 2006 Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study J Hypertens 24 403 408 1:CAS:528:DC%2BD28XhslamurY%3D 10.1097/01.hjh.0000202820.56201.e6 16508590 (Pubitemid 43348255)
46. PA Sarafidis N Khosla GL Bakris 2007 Antihypertensive therapy in the presence of proteinuria Am J Kidney Dis 49 12 26 1:CAS:528:DC%2BD2sXhsFSjsLo%3D 10.1053/j.ajkd.2006.10.014 17185142 (Pubitemid 44918179)
47. GL Bakris PA Sarafidis MR Weir, et al. 2010 ACCOMPLISH Trial Investigators: Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial Lancet 375 1173 1181 1:CAS:528:DC%2BC3cXktlGitr8%3D 10.1016/S0140-6736(09)62100-0 20170948 This recent analysis of the ACCOMPLISH trial showed that antihypertensive combination therapy with ACE inhibitors plus calcium channel blockers is more effective than treatment with ACE inhibitors and diuretics for slowing progression of CKD.